title: TREATMENT WITH CINACALCET INCREASES PLASMA ADIPONECTIN CONCENTRATION IN HEMODIALYZED PATIENTS WITH CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYROIDISM.
abstract: OBJECTIVE
  Cinacalcet increases calcium-sensing receptor (CaSR) sensitivity to serum calcium. CaSR is expressed by adipocytes, and adiponectin is an adipokine with antiatherogenic and insulin-sensitizing properties. The aim of this study was to assess the influence of a 3-month cinacalcet regimen on plasma adiponectin concentration in hemodialyzed patients (HDP) with chronic kidney disease (CKD) and secondary hyperparathyroidism (sHPT).
  
  
  METHODS
  Plasma adiponectin, advanced oxidation protein products (AOPP), serum interleukin-6 (IL-6) and C-reactive protein (CRP) concentrations were assessed in 65 HDP with sHPT treated with cinacalcet (30-120 mg/day) before the first dose and after 3 months of treatment.
  
  
  RESULTS
  There was a significant decrease in serum parathyroid hormone (PTH) concentration: from 1,089 (891-1,286) pg/mL to 775 (574-976) pg/mL after 3 months of treatment (P<.0001). The treatment was associated with a significant (P = .048) increase in plasma adiponectin concentration from 16.9 (14.4-19.5) μg/mL to 17.8 (15.0-20.6) μg/mL. Significant (P = .03) reduction of plasma AOPP concentration was observed from 186.7 (156.7-216.7) pg/mL to 162.6 (141.2-183.9) pg/mL.
  
  
  CONCLUSIONS
  A 3-month cinacalcet regimen increased plasma adiponectin concentrations in HDP with sHPT. Increased adiponectinemia in these patients may be related to reduced oxidative stress.
authors: Piotr
authors: P
authors: Kuczera
authors: Marcin
authors: M
authors: Adamczak
authors: Grzegorz
authors: G
authors: Machnik
authors: Bogusław
authors: B
authors: Okopień
authors: Andrzej
authors: A
authors: Wiecek
mesh_terms: D052242:Adiponectin / Q000097:blood*; D057966:Calcimimetic Agents / Q000494:pharmacology*; D000069449:Cinacalcet / Q000494:pharmacology*; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood* / Q000188:drug therapy; D015850:Interleukin-6; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood*; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000097:blood* / Q000188:drug therapy
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; D057966:Calcimimetic Agents; C508600:IL6 protein, human; D015850:Interleukin-6; D010281:Parathyroid Hormone; D000069449:Cinacalcet